Trial Profile
A prospective, randomized study on intravitreal Ozurdex for preventing recurrent vitreous hemorrhage following pars plana vitrectomy for proliferative diabetic retinopathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary)
- Indications Vitreous haemorrhage
- Focus Therapeutic Use
- 29 Jan 2024 Status changed from recruiting to completed.
- 24 Sep 2014 Planned end date changed from 12 Sep 2013 to 1 Sep 2015 as reported by ClinicalTrials.gov.
- 08 Jun 2012 New trial record